Evidence map›Paper›PMID 33319045›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2020

A study of outcomes, technical safety, and feasibility of D-2 lymphadenectomy in gastric cancer.

Abhijit Talukdar, Srinivas Bannoth, Joydeep Purkayastha, Bibhuti B Borthakur, Deepjyoti Kalita, Gaurav Das, Niju Pegu, Pritesh Singh

Abstract read
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abhijit TalukdarDepartment of surgical oncology Dr. B. Borooah Cancer Institute Guwahati India.
Srinivas BannothDepartment of surgical oncology Dr. B. Borooah Cancer Institute Guwahati India.ORCID https://orcid.org/0000-0003-3547-3345
Joydeep PurkayasthaDepartment of surgical oncology Dr. B. Borooah Cancer Institute Guwahati India.
Bibhuti B BorthakurDepartment of surgical oncology Dr. B. Borooah Cancer Institute Guwahati India.
Deepjyoti KalitaDepartment of surgical oncology Dr. B. Borooah Cancer Institute Guwahati India.
Gaurav DasDepartment of surgical oncology Dr. B. Borooah Cancer Institute Guwahati India.
Niju PeguDepartment of surgical oncology Dr. B. Borooah Cancer Institute Guwahati India.
Pritesh SinghDepartment of surgical oncology Dr. B. Borooah Cancer Institute Guwahati India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimLymph node dissection in gastric cancer had been controversial, but recent data have led us to the conclusion that D-2 dissection should be the standard of care for potentially curable advanced gastric carcinoma. In this study, we present our single-institution experience of D-2 lymph node dissection.

methodsFrom January 2013 to September 2018, 115 patients of gastric cancer were treated with D-2 gastrectomy, 91 of whom met the criteria for study analysis. Data were statistically described as frequencies and percentages where appropriate. Survival curves were plotted using the Kaplan-Meier method, and Cox regression was used to assess the risk among groups. A

resultsThe majority of patients (86.8%) had Clavien-Dindo grade I postoperative surgical complications; 90-day mortality was seen in five (5.5%) patients. Patients with stages I, II, and III had survival rates of 100%, 71.4%; 53.2%, 44.4%; and 27.8%, 28.1%, respectively, for ages <55 and >55 years. Overall recurrence free survival rates were 26 and 28% for <55 years and >55 years, respectively, with a

conclusionsThis retrospective study conducted in our institute on patients with gastric cancer undergoing D-2 lymphadenectomy has shown that the addition of D-2 lymph node dissection, when performed at high-volume centers, have acceptable morbidity and mortality rates. This can be seen from our grades of postoperative surgical complications, 90-day mortality, and overall 5-year survival.

Indexed as

D‐2 dissectiongastric cancerlymphadenectomylymph node

Identifiers

PMID33319045
PMCPMC7731819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.